The present invention relates to the utilisation of myo-inositol hexaphosphate or pharmaceutically-acceptable salts thereof for the manufacture of a medicament destined for the prevention or treatment of a disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. Said compound may be utilised in the manufacture of functional foods, dietetic complements, vitamin complements or nutritional complements or food complements or phytotherapeutic products having properties of inhibition of dissolution of crystals of calcium salts.
